Payment overview · 2025
General Payments
$186,665.18
236 reported records · 14 companies
Healthcare provider profile · identity verified
Peter Shalit, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SEATTLE, WA · NPI 1831181700
Verified facts
What the public records show
CMS Open Payments records show Peter Shalit, M.D. received $186,665.18 in general payments during 2025 across 236 reported records.
ViiV Healthcare Company accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Descovy, Dovato, Pifeltro.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Descovy by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMTUZA as an associated drug or biological on 44 records involving 34 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Symtuza by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Pifeltro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $95,503.94 | 51.2% | 125 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $52,387.89 | 28.1% | 60 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $31,032.50 | 16.6% | 23 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $7,326.90 | 3.9% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.78 | 0.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.39 | 0.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.69 | 0.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.31 | 0.0% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $41.84 | 0.0% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.61 | 0.0% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $34.44 | 0.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.69 | 0.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.74 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.46 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $130,837.50 | 35 |
| Travel and Lodging | $35,056.62 | 76 |
| Consulting Fee | $13,890.00 | 5 |
| Food and Beverage | $6,881.06 | 120 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $51,895.36 | 38 | 2025 |
Source payment records
|
|||||
| Serostim Normalized: serostim |
Drug | EMD Serono, Inc. | $28,880.30 | 17 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $27,450.71 | 24 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $20,273.63 | 18 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $15,877.79 | 14 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $6,635.28 | 6 | 2025 |
Source payment records
|
|||||
| Sunlenca Normalized: sunlenca |
Drug | Gilead Sciences, Inc. | $6,119.93 | 10 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $3,966.90 | 7 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $2,419.73 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.78 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.61 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $52.69 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $41.84 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $34.44 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 103 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Descovy descovy |
2025 | Descovy | 2024 | 191 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
103 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
191 | 19 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SYMTUZA open payments reported associated product |
CMS Open Payments — General Payments 44 supporting records · 34 recipient NPIs · example record 1174329506 |
Symtuza · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 43 |
| Descovy | Emtricitabine/Tenofov Alafenam | 191 | 19 |
| Lisinopril | Lisinopril | 172 | 34 |
| Acyclovir | Acyclovir | 166 | 23 |
| Tivicay | Dolutegravir Sodium | 157 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 25 |
| Omeprazole | Omeprazole | 122 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 116 | 21 |
| Clonazepam | Clonazepam | 116 | 18 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 113 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 112 | 15 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 103 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 22 |
| Gabapentin | Gabapentin | 95 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 16 |
| Prezcobix | Darunavir/Cobicistat | 89 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 87 | suppressed |
| Bupropion Xl | Bupropion Hcl | 86 | 11 |
| Alprazolam | Alprazolam | 85 | 13 |
| Trazodone Hcl | Trazodone Hcl | 85 | 18 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 79 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 78 | suppressed |
| Nevirapine | Nevirapine | 78 | suppressed |
| Metformin Hcl | Metformin Hcl | 77 | 17 |
| Famotidine | Famotidine | 75 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | suppressed |
| Mirtazapine | Mirtazapine | 67 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 57 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Finasteride | Finasteride | 46 | suppressed |
| Isentress Hd | Raltegravir Potassium | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 12 |
| Isentress | Raltegravir Potassium | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 42 | suppressed |
| Indapamide | Indapamide | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Losartan Potassium | Losartan Potassium | 39 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Etravirine | Etravirine | 36 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Furosemide | Furosemide | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Nevirapine Er | Nevirapine | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 11 |
| Testosterone | Testosterone | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Tadalafil | Tadalafil | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Ritonavir | Ritonavir | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Edurant | Rilpivirine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Pifeltro | Doravirine | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Darunavir | Darunavir | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 11 |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Emtricitabine | Emtricitabine | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Prezista | Darunavir | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Tybost | Cobicistat | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Dronabinol | Dronabinol | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Viberzi | Eluxadoline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186,665.18 · 236 records | ViiV Healthcare Company | APRETUDE, APTIMA, Biktarvy, CABENUVA, CAPVAXIVE, COMIRNATY, DOVATO, Descovy, MOUNJARO, NURTEC ODT, NUZYRA, PAXLOVID, PIFELTRO, PREVNAR 20, REPATHA, SPRAVATO, Serostim, Sunlenca, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, Wegovy, XYOSTED, Yeztugo, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error